Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of …